A PILOT STUDY OF MULTIPLEXED PROTEOMIC NEWBORN SCREENING FOR WILSON DISEASE IN WA STATE
<div><p><b>Background:</p> </b><p>Newborn Screening (NBS) is successful in identifying infants with fatal but treatable disorders enabling early intervention with favorable outcomes. Unfortunately, many congenital disorders in particular Wilson disease do not feature specific metabolic biomarkers nor analytical methods suitable for NBS even where highly effective preemptive treatments are available.